Back to Primary literature
Primary-literature peptidehigh evidence

PEPDIA-PLP-002974

TpNPY

Aliases: TpNPY

Normalized sequence

VGGPPKRPESFKSMAELNAYLSDLAGYYTVIGRPRF

36 amino acids

Release PepDiana-V1-20260620

21

Activity records

1

Source papers

21

Positive

0

Negative / threshold

Versioned scientific descriptors

Physicochemical properties and standard representations

calculated sequence and structure

Reported properties

No separate physicochemical property was reported in the primary-literature identity record. PepDiana release values are shown as computed properties.

Computed properties

physchem-20260620

Molecular weight

3988.5261 Da

Molecular formula

C182H280N48O51S

Theoretical pI

9.3998

Net charge at pH 7

1.7357

GRAVY

-0.3639

Instability index

41.9444

Aromaticity

0.1389

Topological polar surface area

1581 Ų

cLogP

-13.9586

Hydrogen-bond donors

55

Hydrogen-bond acceptors

54

Rotatable bonds

124

Method: PepDiana sequence/structure descriptor pipeline

Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6

Calculated: 2026-06-20T11:01:38.358971+00:00

Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200

Sequence representations

representations-20260620

ProForma 2.0

validated simple linear

VGGPPKRPESFKSMAELNAYLSDLAGYYTVIGRPRF

HELM 2.0

validated simple linear

PEPTIDE1{V.G.G.P.P.K.R.P.E.S.F.K.S.M.A.E.L.N.A.Y.L.S.D.L.A.G.Y.Y.T.V.I.G.R.P.R.F}$$$$V2.0

Canonical SMILES

validated

CCC(C)C(NC(=O)C(NC(=O)C(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(Cc1ccc(O)cc1)NC(=O)CNC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(C)NC(=O)C(CC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CCCCN)NC(=O)C(Cc1ccccc1)NC(=O)C(CO)NC(=O)C(CCC(=O)O)NC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C(CCCCN)NC(=O)C1CCCN1C(=O)C1CCCN1C(=O)CNC(=O)CNC(=O)C(N)C(C)C)C(C)O)C(C)C)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1ccccc1)C(=O)O

Isomeric SMILES

validated

CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)CNC(=O)CNC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

Paper-level observations

Experimental evidence grouped by activity

Other 16 records

PMC12858582

16 observations
OtherGeneral ToxicPositive observation
Record detail

Fig. 2A: TpNPY at concentrations of 6–25 μM did not lead to any substantial changes in the survival rate of zebrafish larvae. However, once the concentration arrived at 40 μM, the mortality rate of zebrafish larvae sharply increased, reaching approximately 50%.

Measure
survival_rate
Value
no substantial changes in survival rate at 6–25 μM; ~50% mortality at 40 μM
Target
Danio rerio
Assay
Not reported by source
Source publication
OtherAnti-inflammatoryPositive observation
Record detail

Fig. 2B: the application of 10 mM PTZ dramatically altered the swimming pattern of the zebrafish, as reflected by the increased distance traveled at high speed, whereas these abnormal seizure-like behavior phenotypes were abolished under the treatment of TpNPY (0.75–6 μM).

Measure
percent_inhibition
Value
abolished abnormal seizure-like behavior phenotypes
Target
Danio rerio
Assay
Not reported by source
Source publication
OtherAnti-inflammatoryPositive observation
Record detail

Fig. 2D and E: the mRNA expression levels of these two genes were significantly upregulated in response to PTZ treatment. However, treatment with TpNPY successfully reversed this overexpression.

Measure
fold_change
Value
reversed overexpression of c-fos and npas4a
Target
Danio rerio
Assay
Not reported by source
Source publication
OtherAnti-inflammatoryPositive observation
Record detail

Fig. 3A: after 15 injections, the seizure score in PTZ-treated group arrived at 4.91±0.41; whereas TpNPY treatment at 0.25, 0.5, and 1 mg/kg reduced the seizure score to 4.69±0.32, 3.60±0.47, and 2.62±0.35, respectively.

Measure
qualitative
Value
reduced seizure score from 4.91±0.41 (PTZ) to 2.62±0.35 (1 mg/kg TpNPY)
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherAnti-inflammatoryPositive observation
Record detail

Fig. 3B and C: TpNPY dose-dependently augmented the latency to seizure generation, as well as decreased the duration of generalized seizures.

Measure
qualitative
Value
dose-dependently augmented the latency to seizure generation and decreased the duration of generalized seizures
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherPositive observation
Record detail

Fig. 4A-C: PTZ-treated mice displayed significantly increased anxiety-like behaviors... TpNPY administration substantially reversed these behavioral deficits.

Measure
qualitative
Value
substantially reversed anxiety-like behavioral deficits in OFT
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherPositive observation
Record detail

Fig. 4D and E: PTZ-treated mice exhibited a significantly lower discrimination index... TpNPY treatment restored this cognitive deficit.

Measure
qualitative
Value
restored cognitive deficit in NOR test
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherPositive observation
Record detail

Fig. 4F-K: PTZ-treated mice showed prolonged escape latencies and fewer platform crossings... TpNPY treatment ameliorated these spatial memory impairments.

Measure
qualitative
Value
ameliorated spatial memory impairments in MWM
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherPositive observation
Record detail

Fig. 5A: chronic exposure to PTZ suppressed the neurogenesis in the hippocampal dentate gyrus (DG) in mice... whereas the application of TpNPY significantly promotes the neurogenesis.

Measure
qualitative
Value
promoted neurogenesis in hippocampal DG
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherAntibacterialPositive observation
Record detail

Fig. 5B-D: PTZ treatment significantly decreased the expression levels of TrkB and BDNF, while the administration of TpNPY dose-dependently upregulates these two proteins.

Measure
fold_change
Value
dose-dependently upregulated TrkB and BDNF
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherCytotoxicPositive observation
Record detail

Fig. 6C-E: the reduced cell viability triggered by glutamate was restored by the incubation of TpNPY, as verified by the MTT assay, LDH assay and live-dead cell staining assay.

Measure
cell_viability
Value
restored cell viability reduced by 15 mM glutamate
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherAntibacterialPositive observation
Record detail

Fig. 6F-H: glutamate stimulation significantly decreased the expression of Bcl-2 and increased the expression of Bax in HT22 cells, while treatment with TpNPY abolished these effects.

Measure
fold_change
Value
decreased Bax and increased Bcl-2 expression
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherAntibacterialPositive observation
Record detail

Fig. 7E-H: the application of TpNPY dramatically prevented glutamate-induced calcium overload and ROS accumulation.

Measure
percent_inhibition
Value
prevented glutamate-induced calcium overload and ROS accumulation
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherAntibacterialPositive observation
Record detail

Fig. 7I-K: TpNPY dose-dependently upregulated the protein levels of Nrf2 and HO-1... a significant enhancement in the nuclear translocation of Nrf2 in HT22 cells following the application of TpNPY.

Measure
fold_change
Value
dose-dependently upregulated Nrf2 and HO-1; enhanced nuclear translocation of Nrf2
Target
Mus musculus
Assay
Not reported by source
Source publication
OtherACE InhibitorPositive observation
Record detail

Fig. 1F: the surface plasmon resonance (SPR) analysis revealed a direct interaction between TpNPY and NPY-Y1R, with an equilibrium dissociation constant of 1.98 μM.

Measure
Kd
Value
1.98 μM
Target
NPY-Y1R
Assay
Not reported by source
Source publication
Antioxidant 2 records

PMC12858582

2 observations
AntioxidantAntibacterialPositive observation
Record detail

Fig. 2C and F: the ROS levels in zebrafish larvae upregulated dramatically following PTZ challenge. Nevertheless, treatment with TpNPY mitigated the overaccumulation of ROS elicited by PTZ effectively.

Measure
percent_inhibition
Value
mitigated the overaccumulation of ROS
Target
Danio rerio
Assay
Not reported by source
Source publication
AntioxidantPositive observation
Record detail

Fig. 7A-D: SOD activity, MDA and GSH concentration in the glutamate-treated group reduced sharply and GSH concentration increased dramatically, whereas these effects were effectively counteracted by the application of increasing concentration of TpNPY.

Measure
qualitative
Value
reversed alterations in SOD, MDA, GSH, GSSG caused by glutamate
Target
Mus musculus
Assay
Not reported by source
Source publication
Immunomodulatory 2 records

PMC12858582

2 observations
ImmunomodulatoryAnti-inflammatoryPositive observation
Record detail

Fig. 3D-F: PTZ administration significantly upregulated the expression levels of IL-6, IL-1β, and TNF-α in the mouse hippocampus... In contrast, TpNPY treatment effectively reversed these PTZ-induced elevations in proinflammatory cytokine expression.

Measure
percent_inhibition
Value
effectively reversed PTZ-induced elevations in IL-6, IL-1β, and TNF-α
Target
Mus musculus
Assay
Not reported by source
Source publication
ImmunomodulatoryAnti-inflammatoryPositive observation
Record detail

Fig. 3G-I: the protein expression of GFAP and Iba-1 in the ventral hippocampus of mice was significantly increased upon subconvulsive dose of PTZ... however, these upregulation trends were counteracted by the application of TpNPY.

Measure
percent_inhibition
Value
counteracted upregulation of GFAP and Iba-1
Target
Mus musculus
Assay
Not reported by source
Source publication
Toxicity 1 records

PMC12858582

1 observations
ToxicityCytotoxicPositive observation
Record detail

Fig. 6A: TpNPY ranging from 1.56 to 50 μM did not elicit any significant changes in cell viability after 24 h incubation.

Measure
cell_viability
Value
no significant changes in cell viability at 1.56–50 μM after 24 h
Target
Mus musculus
Assay
Not reported by source
Source publication

Citation and release provenance

Cite this identity as PepDiana record PEPDIA-PLP-002974, release PepDiana-V1-20260620. Experimental observations retain their paper, mention, and activity-record identifiers.

Record updated: 2026-06-22T07:14:26.229247+00:00